Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ...
BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow ...
Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status. We are pleased to announce that the data review ...
ABIONYX Pharma recorded consolidated quarterly sales of nearly €1 million in Q1 2025, down on Q1 2024. This decline is cyclical and reflects a wait-and-see attitude on the part of customers in the ...
VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the ...
NOX-A12 TME Pharma continues its active discussions with potential partners for the NOX-A12 program. TME Pharma has kept the clinical trial for glioblastoma open so that it can be resumed as soon as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results